Limits...
A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.

Hauber AB, Tunceli K, Yang JC, Gantz I, Brodovicz KG, Alexander CM, Davies MJ, Radican L - Diabetes Ther (2015)

Bottom Line: Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes.On average, patients preferred once-weekly to once-daily dosing.For younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment; however, additional research will be required to confirm this hypothesis.

View Article: PubMed Central - PubMed

Affiliation: RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC, USA, abhauber@rti.org.

ABSTRACT

Introduction: Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to elicit preferences for alternative dosing regimens for oral antihyperglycemic therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics.

Methods: Preferences for dosing of oral antihyperglycemic drugs (OAD) were evaluated by surveying patients with T2DM in the United States (US). Survey participants were adult US patients with T2DM who were taking no or only 1 OAD and no injectable therapies. Each patient completed a web-enabled discrete-choice experiment (DCE) including a series of 8 pairs of hypothetical OAD profiles. Each profile was defined by reductions in average glucose, dosing schedule (e.g., once-weekly, once-daily, or twice-daily dosing), chance of mild-to-moderate gastrointestinal side effects, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure, and cost. Each participant also answered a direct question about dosing preference. Random-parameters logit was used to analyze the DCE data. Prespecified subgroups were analyzed.

Results: Of 2,262 patients invited to participate, 923 were included in the analysis (mean age 63 years, 45% male, 79% white). Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes. On average, patients preferred once-weekly to once-daily dosing. Patients not currently taking an OAD had a stronger preference for once-weekly dosing than patients on treatment (P = 0.012). Patients younger than 45 years had a stronger preference for weekly dosing than older patients (P < 0.075).

Conclusions: For younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment; however, additional research will be required to confirm this hypothesis.

No MeSH data available.


Related in: MedlinePlus

Proportion of patients preferring weekly dosing to daily dosing. All proportions are statically significantly different within the overall sample, within the subgroups, and across the subgroup pairings, except the following comparisons: respondents aged 18–44 years and respondents aged 45–64 years (P = 0.065); respondents aged 18–44 years and respondents aged ≥65 years (P = 0.074); and respondents whose T2DM was diagnosed ≤3 years ago and respondents whose T2DM was diagnosed >3 years ago (P = 0.864). T2DM type 2 diabetes mellitus
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4374080&req=5

Fig4: Proportion of patients preferring weekly dosing to daily dosing. All proportions are statically significantly different within the overall sample, within the subgroups, and across the subgroup pairings, except the following comparisons: respondents aged 18–44 years and respondents aged 45–64 years (P = 0.065); respondents aged 18–44 years and respondents aged ≥65 years (P = 0.074); and respondents whose T2DM was diagnosed ≤3 years ago and respondents whose T2DM was diagnosed >3 years ago (P = 0.864). T2DM type 2 diabetes mellitus

Mentions: Patients’ dosing preferences are presented in Fig. 4. Among all patients, 67% preferred weekly dosing to any of the daily-dosing schedules. Among patients not currently taking any OAD, 75% preferred once-weekly dosing to daily-dosing options. This proportion was statistically significantly greater (P = 0.012) than the 65% of patients currently using an OAD who preferred once-weekly dosing over daily dosing. Among younger patients (aged <45 years), 78% preferred once-weekly dosing to daily dosing; in contrast, 66% of patients aged 45–64 years (P = 0.065 vs. the younger age group) and 66% of patients aged 65 years or older (P = 0.074 vs. the younger age group) preferred once-weekly dosing to daily dosing, although these findings were not statistically significant. Similar proportions of patients whose T2DM was diagnosed within the previous 3 years and patients whose T2DM was diagnosed more than 3 years ago preferred once-weekly dosing to daily dosing: 66% of patients with a more recent diagnosis preferred once-weekly dosing, and 67% of patients with a diagnosis more than 3 years ago preferred once-weekly dosing.Fig. 4


A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.

Hauber AB, Tunceli K, Yang JC, Gantz I, Brodovicz KG, Alexander CM, Davies MJ, Radican L - Diabetes Ther (2015)

Proportion of patients preferring weekly dosing to daily dosing. All proportions are statically significantly different within the overall sample, within the subgroups, and across the subgroup pairings, except the following comparisons: respondents aged 18–44 years and respondents aged 45–64 years (P = 0.065); respondents aged 18–44 years and respondents aged ≥65 years (P = 0.074); and respondents whose T2DM was diagnosed ≤3 years ago and respondents whose T2DM was diagnosed >3 years ago (P = 0.864). T2DM type 2 diabetes mellitus
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4374080&req=5

Fig4: Proportion of patients preferring weekly dosing to daily dosing. All proportions are statically significantly different within the overall sample, within the subgroups, and across the subgroup pairings, except the following comparisons: respondents aged 18–44 years and respondents aged 45–64 years (P = 0.065); respondents aged 18–44 years and respondents aged ≥65 years (P = 0.074); and respondents whose T2DM was diagnosed ≤3 years ago and respondents whose T2DM was diagnosed >3 years ago (P = 0.864). T2DM type 2 diabetes mellitus
Mentions: Patients’ dosing preferences are presented in Fig. 4. Among all patients, 67% preferred weekly dosing to any of the daily-dosing schedules. Among patients not currently taking any OAD, 75% preferred once-weekly dosing to daily-dosing options. This proportion was statistically significantly greater (P = 0.012) than the 65% of patients currently using an OAD who preferred once-weekly dosing over daily dosing. Among younger patients (aged <45 years), 78% preferred once-weekly dosing to daily dosing; in contrast, 66% of patients aged 45–64 years (P = 0.065 vs. the younger age group) and 66% of patients aged 65 years or older (P = 0.074 vs. the younger age group) preferred once-weekly dosing to daily dosing, although these findings were not statistically significant. Similar proportions of patients whose T2DM was diagnosed within the previous 3 years and patients whose T2DM was diagnosed more than 3 years ago preferred once-weekly dosing to daily dosing: 66% of patients with a more recent diagnosis preferred once-weekly dosing, and 67% of patients with a diagnosis more than 3 years ago preferred once-weekly dosing.Fig. 4

Bottom Line: Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes.On average, patients preferred once-weekly to once-daily dosing.For younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment; however, additional research will be required to confirm this hypothesis.

View Article: PubMed Central - PubMed

Affiliation: RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC, USA, abhauber@rti.org.

ABSTRACT

Introduction: Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to elicit preferences for alternative dosing regimens for oral antihyperglycemic therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics.

Methods: Preferences for dosing of oral antihyperglycemic drugs (OAD) were evaluated by surveying patients with T2DM in the United States (US). Survey participants were adult US patients with T2DM who were taking no or only 1 OAD and no injectable therapies. Each patient completed a web-enabled discrete-choice experiment (DCE) including a series of 8 pairs of hypothetical OAD profiles. Each profile was defined by reductions in average glucose, dosing schedule (e.g., once-weekly, once-daily, or twice-daily dosing), chance of mild-to-moderate gastrointestinal side effects, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure, and cost. Each participant also answered a direct question about dosing preference. Random-parameters logit was used to analyze the DCE data. Prespecified subgroups were analyzed.

Results: Of 2,262 patients invited to participate, 923 were included in the analysis (mean age 63 years, 45% male, 79% white). Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes. On average, patients preferred once-weekly to once-daily dosing. Patients not currently taking an OAD had a stronger preference for once-weekly dosing than patients on treatment (P = 0.012). Patients younger than 45 years had a stronger preference for weekly dosing than older patients (P < 0.075).

Conclusions: For younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment; however, additional research will be required to confirm this hypothesis.

No MeSH data available.


Related in: MedlinePlus